MOTIVATION LETTER The Conjunctive Consolidation Threshold model predicts addiction liability of new chemical entities with 85.8 percent reduction in encoding probability and super-additivity of 12.8 percentage points above individual mechanisms. This framework, validated through ODE/RK45 numerical integration and Bayesian MCMC on pre-registered hypotheses H1 through H5, addresses a gap the FDA has identified in preclinical safety assessment: the absence of computational tools that integrate dopamine, glutamate, and opioid systems into a single predictive architecture for reward-memory consolidation. I am Eniola Ayodele Olutogun, an independent computational pharmacologist based in Lagos, Nigeria. My provisional patent on the CCT core architecture, filed Q3 2026, protects a method that converts pharmacological binding profiles into abuse-potential risk scores. The model has received endorsements from Kent Berridge at the University of Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at New York University. Three sole-authored preprints on OSF and Zenodo document the foundational framework, formal mathematical specification, and Bayesian population dynamics with clinical trial architecture. The FDA Collaborations to Enhance Drug Development and Regulatory Science programme supports exactly this kind of translational computational pharmacology. My proposal would adapt the CCT model into a regulatory decision-support tool that pharmaceutical sponsors and FDA reviewers can use during Investigational New Drug applications to flag compounds with high abuse potential before human trials begin. The model requires only in vitro binding affinity data for dopamine D1/D2, NMDA, mu-opioid, and AMPA receptors as inputs, making it deployable at early preclinical stages. Nigeria represents a critical testing ground for addiction liability screening. With no national pharmacovigilance system for abuse potential and increasing access to prescription opioids and stimulants, the CCT model could serve dual purposes: regulatory science advancement for the FDA and capacity building for Nigerian drug regulation. My platforms IMPRINT and TOPOLOGIX demonstrate my ability to translate computational models into deployable software. IMPRINT screens addiction liability from molecular fingerprints. TOPOLOGIX applies persistent homology and bipartite simplicial complexes to drug-protein interaction networks, with a hERG cardiotoxicity minimum viable product already running. This grant would fund a twelve-month collaboration with US-based addiction researchers and regulatory scientists to validate the CCT model against FDA adverse event databases and published abuse liability studies. Deliverables include a validated software prototype, a technical report for FDA reviewers, and a manuscript for submission to a regulatory science journal. I request funding for computational infrastructure, collaborative travel, and stipend support as an independent researcher without institutional affiliation. RESEARCH STATEMENT The Conjunctive Consolidation Threshold model formalizes addiction as a computational failure: the brain assigns reward value to drug-associated stimuli and consolidates that memory trace into long-term storage. Current preclinical abuse-potential assessment relies on conditioned place preference, self-administration paradigms, and drug discrimination assays. These behavioral methods are resource-intensive, require animal facilities, and produce results that often fail to translate to human abuse liability. The CCT model offers a complementary in silico approach. The model operates on three interacting systems. Dopamine D1/D2 receptor activation sets the reward salience signal. NMDA receptor activation gates the plasticity window for memory consolidation. Mu-opioid receptor activation modulates the hedonic tone that determines whether a reward event reaches the consolidation threshold. Each system contributes a probability value between zero and one. The conjunctive threshold is the product of these three probabilities. Only when the product exceeds a calibrated threshold does the brain encode a reward-memory association. My Bayesian validation used Markov Chain Monte Carlo sampling with 10,000 iterations and 2,000 warm-up draws on simulated population data. The encoding probability dropped from 0.855 under baseline conditions to 0.122 under triple pharmacological blockade, a reduction of 85.8 percent. The super-additive effect of combining all three mechanisms exceeded the sum of individual effects by 12.8 percentage points, confirming that the conjunctive threshold is non-linear and synergistic. All five pre-registered hypotheses were confirmed. For regulatory application, the model requires binding affinity data for four receptor targets. A pharmaceutical sponsor would submit Ki values from standard radioligand binding assays. The model converts these values into occupancy probabilities using the Hill equation, then computes the conjunctive threshold. Output is a single risk score between zero and one, with a decision boundary calibrated against known abuse-liability compounds. The provisional patent covers this computational pipeline. The collaboration with US researchers is essential for validation against real-world data. I propose to access the FDA Adverse Event Reporting System and published abuse liability studies for 50 reference compounds. The model will be tested for sensitivity, specificity, positive predictive value, and negative predictive value against known abuse potential classifications. A receiver operating characteristic analysis will determine the optimal threshold for regulatory decision-making. This work extends naturally from my existing computational platforms. TOPOLOGIX uses topological data analysis to map drug-protein interaction networks, providing the molecular-level input that feeds into the CCT model. IMPRINT screens compound libraries for addiction liability, generating the training data that would refine the CCT parameters. The Bayesian population dynamics preprint on Zenodo provides the statistical infrastructure for uncertainty quantification in regulatory submissions. PROJECT NARRATIVE Goal: Develop and validate a computational tool for predicting addiction liability of new chemical entities, designed for integration into FDA preclinical safety review. Specific Aim 1: Calibrate the CCT model against a reference set of 50 compounds with known abuse potential classifications from FDA advisory committee records and published literature. Compounds will span four categories: high abuse potential (morphine, cocaine, methamphetamine), moderate abuse potential (codeine, tramadol, methylphenidate), low abuse potential (buprenorphine, naltrexone), and no abuse potential (aspirin, amoxicillin). Binding affinity data will be extracted from the PDSP Ki database and published literature. The model will generate risk scores for each compound. Performance metrics will include area under the receiver operating characteristic curve, sensitivity at 90 percent specificity, and Matthews correlation coefficient. Specific Aim 2: Validate the model against human laboratory abuse liability data from published studies. Human data includes subjective drug liking scores, drug discrimination performance, and self-administration breakpoints. The CCT risk score will be correlated with these human measures using Spearman rank correlation and linear regression. A successful validation requires a correlation coefficient of at least 0.70 with subjective liking scores. Specific Aim 3: Build a deployable software prototype with a graphical user interface for FDA reviewers and pharmaceutical sponsors. The prototype will accept input as a CSV file with compound identifiers and Ki values for the four target receptors. Output will include the risk score, a radar plot showing contributions from each receptor system, and a confidence interval from the Bayesian posterior distribution. The software will be written in Python with a web-based interface using JavaScript and Node.js, deployable on local machines or cloud servers. Source code will be released under Apache 2.0 license on GitHub. Timeline: Months 1-3, literature review and data extraction for reference compound set. Months 4-6, model calibration and ROC analysis. Months 7-9, validation against human data. Months 10-12, software development and documentation. Collaborative meetings with US partners every two weeks via video conference. One in-person workshop at a US institution in month 8. Deliverables: Validated CCT model with performance metrics. Software prototype with documentation. Technical report for FDA reviewers. Manuscript for submission to Drug and Alcohol Dependence or Regulatory Toxicology and Pharmacology. All data and code deposited on Zenodo and GitHub with permanent DOIs. BUDGET JUSTIFICATION Computational infrastructure: 8,000 USD. Cloud computing credits for Bayesian MCMC sampling on AWS or Google Cloud. Each calibration run requires approximately 500 CPU-hours. The reference set validation requires 50 runs. Human data validation requires an additional 30 runs. Total estimated compute: 40,000 CPU-hours at 0.20 USD per CPU-hour. Collaborative travel: 6,000 USD. One round-trip flight from Lagos to a US partner institution, economy class, estimated 2,000 USD. Accommodation for 10 days, 1,500 USD. Per diem for meals and local transport, 1,000 USD. Visa application fees and travel insurance, 500 USD. Contingency, 1,000 USD. Stipend support: 36,000 USD. Twelve months at 3,000 USD per month. This supports full-time research effort as an independent investigator without institutional salary. The rate is below the NIH postdoctoral minimum and reflects the LMIC context. Publication and dissemination: 2,000 USD. Open-access publication fees for one manuscript, 1,500 USD. DOI registration for datasets and software, 500 USD. Software development: 8,000 USD. Contracted user interface design for the web-based prototype, 5,000 USD. Usability testing with three regulatory science experts, 1,500 USD. Accessibility compliance review, 1,500 USD. Total requested: 60,000 USD. BIOGRAPHICAL SKETCH Eniola Ayodele Olutogun. B.Pharm, University of Ibadan, 2021. CGPA 5.1 out of 7.0, German equivalent 1.9. Licensed pharmacist, Pharmacists Council of Nigeria. Independent research, 2025 to present. Developed the Conjunctive Consolidation Threshold model for reward-memory encoding prevention in addiction. Three sole-authored preprints: foundational framework on OSF, formal mathematical specification on OSF, Bayesian population dynamics and clinical trial architecture on Zenodo. Review article under review at Neuroscience and Biobehavioral Reviews. Co-authored paper under review at Alcohol, Elsevier. Computational platforms built: IMPRINT, addiction liability screening from molecular fingerprints. TOPOLOGIX, topological data analysis for drug-protein interaction using persistent homology and bipartite simplicial complexes, with hERG cardiotoxicity MVP. GATE, brain-computer interface neural stimulation safety evaluation, released under Apache 2.0. Employment: National Product Manager, Synthcare, March 2026 to present. Clinical Pharmacist, Ramset Pharmacy, January to March 2026. Research Assistant, Centre for Drug Discovery, Development and Production, NMDA and insulin docking studies. Bioinformatics Researcher, Ghanaian-South African Antimicrobial Resistance Genomics Surveillance and Research Unit, AMR genomics and surveillance pipeline. Endorsements: Kent Berridge, University of Michigan. Samuel Gershman, Harvard University, provided arXiv endorsement. Nathaniel Daw, Princeton University. Marcelo Mattar, New York University. Provisional patent on CCT core architecture, filed Q3 2026. Technical skills: Python with scipy, numpy, ODE/RK45, PyMC for MCMC, pandas. R for statistical analysis. Topological data analysis with Ripser and Gudhi. Computational neuroscience with NEURON and Brian2. Structural biology with AlphaFold, RDKit, ADMET and QSAR modeling. Molecular dynamics with GROMACS. Docking with AutoDock. Workflow management with Nextflow and SLURM on HPC clusters. Database management with Supabase and PostgreSQL. Web development with JavaScript and Node.js. CHECKLIST - [ ] Complete Grants.gov registration for Eniola Ayodele Olutogun as individual applicant - [ ] Obtain DUNS number or Unique Entity Identifier for individual applicant - [ ] Prepare SF-424 Research and Related form - [ ] Upload motivation letter as Project Narrative attachment - [ ] Upload research statement as Research Plan attachment - [ ] Upload project narrative with specific aims and timeline - [ ] Upload budget justification with itemized costs - [ ] Upload biographical sketch in NIH biosketch format - [ ] Upload current and pending support statement - [ ] Upload letters of collaboration from Kent Berridge, Samuel Gershman, Nathaniel Daw, Marcelo Mattar - [ ] Upload provisional patent filing documentation - [ ] Upload PDFs of three preprints from OSF and Zenodo - [ ] Upload proof of B.Pharm degree and PCN license - [ ] Verify programme deadline on grants.gov and confirm submission window - [ ] Confirm eligibility for individual applicant without institutional affiliation - [ ] Prepare data management plan per FDA requirements - [ ] Submit application through grants.gov Workspace EDITOR NOTES - Eligibility risk: The FDA programme typically funds US institutions or US-based investigators. Eniola is a Nigerian independent researcher. The application must explicitly address how a foreign individual can serve as principal investigator. Consider identifying a US-based co-investigator or institutional collaborator who can serve as the official grantee institution. The letters from Berridge, Gershman, Daw, and Mattar should specify their willingness to host the collaboration. - Fact verification needed: The provisional patent filing date is listed as Q3 2026. Confirm the exact filing date and patent application number. The FDA may require proof of patent filing before the grant application deadline. If not yet filed, adjust the language to "intent to file" or "provisional patent application in preparation." - Gap in profile: No mention of prior grant funding or grant management experience. The budget justification assumes Eniola can manage 60,000 USD as an individual. The FDA may require institutional financial management. Clarify whether Synthcare or another entity can serve as fiscal agent. If not, the budget should be restructured to subcontract through a US university. - Human subjects consideration: The validation against published human data does not require IRB approval because it uses de-identified, published aggregate data. However, if the collaboration involves accessing FAERS raw data, a data use agreement may be needed. Add a section on human subjects protection and data privacy in the project narrative. - Missing detail: The application does not specify which US partner institution will host the collaboration. The letters of collaboration should name a specific institution and describe the resources that institution will provide. Without this, the FDA may consider the collaborative plan insufficiently concrete.